Benzinga | Jan 21, 2021 07:02AM EST

Genetic Technologies Also Discusses Expansion Into Germline Testing

Germline Testing Division

Expanding the scope of the GeneType Tests

As previously outlined, Genetic Technologies established the Germline Testing division following the strategic decision to offer hereditary testing for inherited cancer. The initial product focus for the division will be on BRCA testing to align with the Company's GeneType for Breast Cancer product and Lynch Syndrome testing to align with the Company's GeneType for Colorectal Cancer. This approach provides several strategic benefits, being the ability to identify cancer risk across the whole spectrum of cancer causation, from hereditary cancers caused by monogenic mutations to sporadic cancers with a polygenic, multifactorial cause.

Further announcements regarding the progression within the hereditary cancer testing will be provided as the Company progresses with the development and validation process.

Genetic Technologies Limited aims to provide a comprehensive risk assessment service across the full spectrum from sporadic to inherited disease.